Tin tức & Cập nhật

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
02 Jul 2024
Subcutaneous atezolizumab favoured over intravenous infusion
Subcutaneous atezolizumab favoured over intravenous infusion
02 Jul 2024 bởiJairia Dela Cruz

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Subcutaneous atezolizumab favoured over intravenous infusion
02 Jul 2024